Antitumor activity and immune response induction of a dual agonist of toll-like receptors 7 and 8

Molecular Cancer Therapeutics

Volumn 9, Issue 6, 2010, Pages 1788-1797

  Wang, Daqing ^a   Precopio, Melissa ^a   Lan, Tao ^a   Yu, Dong ^a   Tang, Jimmy X ^a   Kandimalla, Ekambar R ^a   Agrawal, Sudhir ^a  

^a HYBRIDON INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TOLL LIKE RECEPTOR 7 AGONIST; TOLL LIKE RECEPTOR 8 AGONIST; TOLL LIKE RECEPTOR AGONIST; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; COLON CARCINOMA; FEMALE; IMMUNE RESPONSE; LUNG CARCINOMA; LUNG METASTASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; SECRETORY CELL;

ANIMALS; ANTIGENS, NEOPLASM; CELL LINE, TUMOR; COLONIC NEOPLASMS; CYTOKINES; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SCREENING ASSAYS, ANTITUMOR; EPITOPES; IMMUNITY; IMMUNOLOGIC MEMORY; INTERFERON-GAMMA; INTERLEUKIN-12; LUNG NEOPLASMS; MICE; MYELOID DIFFERENTIATION FACTOR 88; OLIGORIBONUCLEOTIDES; SIGNAL TRANSDUCTION; SURVIVAL ANALYSIS; T-LYMPHOCYTES, REGULATORY; TOLL-LIKE RECEPTOR 7; TOLL-LIKE RECEPTOR 8;

EID: 77953435969     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-09-1198     Document Type: Article

References (42)

1. Akira S, Uematsu S, Takeuchi O. Pathogen recognition and innate immunity. Cell 2006;124:783-801.
2. Heil F, Hemmi H, Hochrein H, et al. Species-specific recognition of single-stranded RNA via Toll-like receptor 7 and 8. Science 2004; 303:1526-9. (Pubitemid 38314424)
3. Lund JM, Alexopoulou L, Sato A, et al. Recognition of single-stranded RNA viruses by Toll-like receptor 7. Proc Natl Acad Sci U S A 2004; 101:5598-603. (Pubitemid 38481202)
4. Iwasaki A, Medzhitov R. Toll-like receptor control of the adaptive immune responses. Nat Immunol 2004;5:987-95. (Pubitemid 41057715)
5. Agrawal S, Kandimalla ER. Synthetic agonists of Toll-like receptors 7, 8 and 9. Biochem Soc Trans 2007;35:1461-7.
6. Hersh EM, Gutterman JU, Mavligit GM. BCG as adjuvant immunotherapy for neoplasia. Annu Rev Med 1977;28:489-515.
7. Bhattacharjee BN, Akira S. Toll-like receptor signaling: Emerging opportunities in human diseases and medicine. Curr Immunol Rev 2005;1:81-90.
8. Diebold SS. Recognition of viral single-stranded RNA by Toll-like receptors. Adv Drug Deliv Rev 2008;60:813-23.
9. Chuang TH, Ulevitch RJ. Cloning and characterization of a subfamily of human Toll-like receptors: hTLR7, hTLR8 and hTLR9. Eur Cytokine Netw 2000;11:372-8.
10. Agrawal S, Tang JY, Sun D, Sarin PS, Zamecnik PC. Synthesis and anti-HIV activity of oligoribonucleotides and their phosphorothioate analogs. Ann N Y Acad Sci 1992;660:2-10. (Pubitemid 23054710)
11. Dow S. Liposome-nucleic acid immunotherapeutics. Expert Opin Drug Deliv 2008;5:11-24.
12. Hoerr I, Obst R, Rammensee HG, Jung G. In vivo application of RNA leads to induction of specific cytotoxic T lymphocytes and antibodies. Eur J Immunol 2000;30:1-7.
13. Forsbach A, Nemorin JG, Montino C, et al. Identification of RNA sequence motifs stimulating sequence-specific TLR8-dependent immune responses. J Immunol 2008;180:3729-38.
14. Lan T, Kandimalla ER, Yu D, et al. Stabilized immune modulatory RNA compounds as agonists of Toll-like receptors 7 and 8. Proc Natl Acad Sci U S A 2007;104:13750-5.
15. Lan T, Putta MR, Wang D, et al. Synthetic oligoribonucleotides-containing secondary structures act as agonists of Toll-like receptors 7 and 8. Biochem Biophys Res Commun 2009;386:443-8.
16. Lan T, Bhagat L, Wang D, Dai M, Kandimalla ER, Agrawal S. Synthetic oligoribonucleotides containing arabinonucleotides act as agonists of TLR7 and 8. Bioorg Med Chem Lett 2009;19:2044-7.
17. Lan T, Dai M, Wang D, Zhu FG, Kandimalla ER, Agrawal S. Toll-like receptor 7 selective synthetic oligoribonucleotide agonists: Synthesis and structure-activity relationship studies. J Med Chem 2009;52:6871-9.
18. Wang M, Bronte B, Chen PW, et al. Active immunotherapy of cancer with a nonreplicated recombinant fowlpox virus encoding a model tumor-associated antigen. J Immunol 1995;154:4685-92.
19. Wang D, Li Y, Yu D, Song SS, Kandimalla ER, Agrawal S. Immunopharmacological and antitumor effects of second-generation immunomodulatory oligonucleotides containing synthetic CpR motif. Int J Oncol 2004;24:901-8.
20. Huang AY, Gulden PH, Woods AS, et al. The immunodominant major histocompatibility complex class I-restricted antigen of a murine colon tumor derives from an endogenous retroviral gene product. Proc Natl Acad Sci U S A 1996;93:9730-5.
21. Li M, Huang X, Zhu Z, et al. Immune response against 3LL Lewis lung carcinoma potentiates the therapeutic efficacy of endostatin. J Immunother 2001;24:472-81.
22. Herber DL, Nagaraj S, Djeu JY, Gabrilovich DI. Mechanism and therapeutic reversal of immune suppression in cancer. Cancer Res 2007;67:5067-9.
23. Diebold SS, Kaisho T, Hemmi H, Akira S, Reis-e-Sousa C. Innate antiviral responses by means of TLR7-mediated recognition of single-stranded RNA. Science 2004;303:1529-31.
24. Lee J, Chuang TH, Redecke V, et al. Molecular basis for the stimulatory activity of guanine nucleoside analogs: activation of Toll-like receptor 7. Proc Natl Acad Sci U S A 2003;100:6646-51.
25. Szeimies RM, Gerritsen MJ, Gupta G, et al. Imiquimod 5% cream for the treatment of actinic keratosis: results from a phase III, randomized, double-blind, vehicle-controlled, clinical trial with histology. J Am Acad Dermatol 2004;51:547-55.
26. Geisse JK, Rich P, Pandya A, et al. Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: a double-blind, randomized, vehicle-controlled study. J Am Acad Dermatol 2002; 47:390-8.
27. Karlsson A, Jägervall K, Utkovic H, et al. Intra-colonic administration of the TLR7 agonist R-848 induces an acute local and systemic inflammation in mice. Biochem Biophys Res Commun 2008;367:242-8.
28. Broomfield SA, van der Most RG, Prosser AC, et al. Locally Administered TLR7 agonists drive systemic antitumor immune responses that are enhanced by anti-CD40 immunotherapy. J Immunol 2009; 182:5217-24.
29. Schon MP, Schon M, Klotz KN. The small antitumoral immune response modifier imiquimod interacts with adenosine receptor signaling in a TLR7- and TLR8-independent fashion. J Invest Dermatol 2006;126:1338-47.
30. Zagon IS, Donahue RN, Rogosnitzky M, McLaughlin PJ. Imiquimod upregulates the opioid growth factor receptor to inhibit cell proliferation independent of immune function. Exp Biol Med 2008;233: 968-79.
31. Kamath AT, Sheasby CE, Tough DF. Dendritic cells and NK cells stimulate bystander T cell activation in response to TLR activation through secretion of IFN-α, β and γ. J Immunol 2005;174:767-76.
32. Scheel B, Braedel S, Probst J, et al. Immunostimulating capacities of stabilized RNA molecules. Eur J Immunol 2004;34:537-47.
33. Scheel B, Aulwurm S, Probst J, et al. Therapeutic anti-tumor immunity triggered by injections of immunostimulating single-stranded RNA. Eur J Immunol 2006;36:2807-16.
34. Bourquin C, Schmidt L, Hornung V, et al. Immunostimulatory RNA oligonucleotides trigger an antigen-specific cytotoxic T-cell and IgG2a response. Blood 2007;109:2953-60.
35. Diebold SS, Massacrier C, Akira S, Paturel C, Morel Y, Reis-E-Sousa C. Nucleic acid agonists for Toll-like receptor 7 are defined by the presence of uridine ribonucleotides. Eur J Immunol 2006;36: 3256-67.
36. Hornung V, Guenthner-Biller M, Bourquin C, et al. Sequence-specific potent induction of IFN-α by short interfering RNA in plasmacytoid denderitic cells through TLR7. Nat Med 2005;11:263-70.
37. Grabbe S, Beissert S, Schearz T, Granstein RD. Dendritic cells as initiators of tumor immune responses: a possible strategy for tumor immunotherapy? Immunol Today 1995;16:117-21.
38. Houghton AN. Cancer antigens: immune recognition of self and altered self. J Exp Med 1996;180:1-4.
39. Gabrilovich DI, Ciernik IF, Carbone DP. Dendritic cells in antitumor immune responses. 1. Defective antigen presentation in tumor-bearing hosts. Cell Immunol 1996;170:101-10.
40. Ioannides CG, Whiteside TL. T cell recognition of human tumors: implications for molecular immunotherapy of cancer. Clin Immunol Immunopathol 1993;66:91-106.
41. Curiel TJ. Tregs and rethinking cancer immunotherapy. J Clin Invest 2007;117:1167-74.
42. Yang ZZ, Ansell SM. The role of Treg cells in the cancer immunological response. Am J Immunol 2009;5:17-28.